Loss of IDH1 and IDH2 mutations during the evolution of metastatic chondrosarcoma
William Cross, Iben Lyskjær, Christopher Davies, Abigail Bunkum et autres
4 citationsGenome biology
Emma Beddowes
Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.
45Publications signalées
1169Citations signalées
5Affiliations récentes
Institutions déclarées
Domaines associés
PI3K/AKT/mTOR signaling in cancerCancer Genomics and DiagnosticsCancer therapeutics and mechanismsCancer Treatment and PharmacologyAdvanced Breast Cancer Therapies
Publications récentes
A large‐scale retrospective study in metastatic breast cancer patients using circulating tumour DNA and machine learning to predict treatment outcome and progression‐free survival
Emma Beddowes, Mario Ortega Duran, Solon Karapanagiotis, Alistair Martin et autres
5 citationsMolecular Oncology
Real-World Outcomes Of First Line Chemotherapy In Advanced/Recurrent Endometrial Cancer According To Mismatch Repair Protein (MMR) Status By Immunohistochemistry (IHC), Guy’s Cancer Experience
Eirini Konstantinidou, Jiaqi Shi, Andrea D’Souza, Emma Beddowes et autres
0 citationsInternational Journal of Gynecological Cancer
Public and patient involvement: a survey on knowledge, experience and opinions among researchers within a precision oncology European project
Paola Mosconi, Cinzia Colombo, Pasquale Paletta, Laura Gangeri et autres
10 citationsBMC Cancer
Copy number architectures define treatment-mediated selection of lethal prostate cancer clones
A. M. Mahedi Hasan, Paolo Cremaschi, Daniel Wetterskog, Anuradha Jayaram et autres
12 citationsNature Communications
Comparison of tumor‐informed and tumor‐naïve sequencing assays for ctDNA detection in breast cancer
Ángela Santonja, Wendy N. Cooper, Matthew Eldridge, Paul A. Edwards et autres
63 citationsEMBO Molecular Medicine
Figure S3 from POSEIDON Trial Phase 1b Results: Safety, Efficacy and Circulating Tumor DNA Response of the Beta Isoform-Sparing PI3K Inhibitor Taselisib (GDC-0032) Combined with Tamoxifen in Hormone Receptor Positive Metastatic Breast Cancer Patients
Richard D. Baird, Annelot G.J. van Rossum, Mafalda Oliveira, Karin Beelen et autres
0 citations
Figure S1 from POSEIDON Trial Phase 1b Results: Safety, Efficacy and Circulating Tumor DNA Response of the Beta Isoform-Sparing PI3K Inhibitor Taselisib (GDC-0032) Combined with Tamoxifen in Hormone Receptor Positive Metastatic Breast Cancer Patients
Richard D. Baird, Annelot G.J. van Rossum, Mafalda Oliveira, Karin Beelen et autres
0 citations
Supplementary Methods from POSEIDON Trial Phase 1b Results: Safety, Efficacy and Circulating Tumor DNA Response of the Beta Isoform-Sparing PI3K Inhibitor Taselisib (GDC-0032) Combined with Tamoxifen in Hormone Receptor Positive Metastatic Breast Cancer Patients
Richard D. Baird, Annelot G.J. van Rossum, Mafalda Oliveira, Karin Beelen et autres
0 citations
Figure S2 from POSEIDON Trial Phase 1b Results: Safety, Efficacy and Circulating Tumor DNA Response of the Beta Isoform-Sparing PI3K Inhibitor Taselisib (GDC-0032) Combined with Tamoxifen in Hormone Receptor Positive Metastatic Breast Cancer Patients
Richard D. Baird, Annelot G.J. van Rossum, Mafalda Oliveira, Karin Beelen et autres
0 citations
Figure S4 from POSEIDON Trial Phase 1b Results: Safety, Efficacy and Circulating Tumor DNA Response of the Beta Isoform-Sparing PI3K Inhibitor Taselisib (GDC-0032) Combined with Tamoxifen in Hormone Receptor Positive Metastatic Breast Cancer Patients
Richard D. Baird, Annelot G.J. van Rossum, Mafalda Oliveira, Karin Beelen et autres
0 citations
Figure S1 from POSEIDON Trial Phase 1b Results: Safety, Efficacy and Circulating Tumor DNA Response of the Beta Isoform-Sparing PI3K Inhibitor Taselisib (GDC-0032) Combined with Tamoxifen in Hormone Receptor Positive Metastatic Breast Cancer Patients
Richard D. Baird, Annelot G.J. van Rossum, Mafalda Oliveira, Karin Beelen et autres
0 citations
BNTIC News n’est pas le producteur de ces données. Recherche à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, ROR et la Banque mondiale, sans clé ; OpenAlex reste optionnel. Aucun service payant requis, aucune donnée externe enregistrée en base. Sources et limites.